Oslo Sports Trauma Research Center, Department of Sports Medicine, Norwegian School of Sport Sciences, Ullevaal Stadion, Oslo, Norway.
Am J Sports Med. 2011 Nov;39(11):2377-80. doi: 10.1177/0363546511417097. Epub 2011 Aug 12.
A randomized controlled study has shown good clinical results after treatment with sclerosing injections into the area with neovessels in patients with patellar tendinopathy, but no study has investigated medium- or long-term outcomes.
This study investigates the effect of sclerosing treatment 44 months (range, 42-47 months) after start of treatment.
Case series; Level of evidence, 4.
Patients with a diagnosis of jumper's knee and neovascularization corresponding to the painful area were recruited and treated with ultrasound-guided sclerosing injections using polidocanol. Primary outcome was Victorian Institute of Sport Assessment (VISA) score, which was recorded before the start of treatment, after 12 months, and 44 months after the start of the study period.
Twelve of the 29 patients (14 tendons) who were followed up at 44 months had undergone arthroscopic surgery after sclerosing treatment, either to the patellar tendon (n = 6) or for other intra-articular lesions (n = 8). For patients who did not receive additional treatment after the sclerosing injections (n = 23 tendons), VISA score was 55 (range, 28-71) at baseline and 81 (range, 39-100) at 12-month follow-up (P < .001 vs baseline).Their VISA score at 44 months' follow-up was 89 (range, 73-100; P = .047 vs 12 months). For patients who went through arthroscopic tendon surgery, VISA score was 53 (range, 39-71) at baseline and 71 before surgery (range, 48-98; P = .14 vs baseline). Their VISA score at 44 months was 91 (range, 76-100; P = .0.16 vs 12 months; P = .005 vs baseline). For patients who went through non-tendon surgery, VISA score was 45 (range, 15-69) at baseline and 57 (range, 32-95) before surgery (P = .29 vs baseline). Their VISA score at 44 months was 92 (range, 72-100; P = .006 vs before surgery; P < .001 vs baseline).
Sclerosing treatment with polidocanol was effective for the majority of the patients. Nevertheless, one-third elected to seek additional treatment through arthroscopic surgery during the 44-month follow-up period.
一项随机对照研究表明,在髌腱病患者的新生血管区域进行硬化注射治疗后,临床效果良好,但尚无研究调查中-长期结果。
本研究调查了治疗开始后 44 个月(范围 42-47 个月)硬化治疗的效果。
病例系列;证据水平,4。
招募了诊断为跳跃膝且疼痛区域存在新生血管的患者,并使用聚多卡醇进行超声引导下的硬化注射治疗。主要结局指标为维多利亚运动评估(VISA)评分,在治疗开始前、治疗后 12 个月和研究开始后 44 个月进行记录。
29 名接受随访的患者中有 12 名(14 条肌腱)在硬化治疗后接受了关节镜手术,其中 6 名患者接受了髌腱手术,8 名患者接受了其他关节内病变手术。对于接受硬化注射治疗后未接受额外治疗的 23 条肌腱患者,VISA 评分在基线时为 55(范围 28-71),在 12 个月随访时为 81(范围 39-100)(P<.001 与基线相比)。他们在 44 个月随访时的 VISA 评分为 89(范围 73-100;P=.047 与 12 个月相比)。对于接受关节镜肌腱手术的患者,基线时的 VISA 评分为 53(范围 39-71),手术前为 71(范围 48-98;P=.14 与基线相比)。他们在 44 个月时的 VISA 评分为 91(范围 76-100;P=.0.16 与 12 个月相比;P=.005 与基线相比)。对于接受非肌腱手术的患者,基线时的 VISA 评分为 45(范围 15-69),手术前为 57(范围 32-95)(P=.29 与基线相比)。他们在 44 个月时的 VISA 评分为 92(范围 72-100;P=.006 与手术前相比;P<.001 与基线相比)。
聚多卡醇硬化治疗对大多数患者有效。然而,在 44 个月的随访期间,有三分之一的患者选择通过关节镜手术寻求额外治疗。